Wanbury Limited

Wanbury Limited company information, Employees & Contact Information

Explore related pages

Related company profiles:

Corporate Profile Towards Better Healthcare… Wanbury Limited, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation. Wanbury’s major thrust area lies in Active Pharmaceutical Ingredient (API) sale in over 70 countries and Pan-India Formulation presence. Active Pharmaceutical Ingredient : Wanbury has a basket of over 13 API products. It is the largest manufacturer of Metformin with over 8500 tons per year. It is the largest exporter of Tramadol to the US market. Wanbury exports to over 50 countries, 65% of which comprises of regulated markets. Has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. Has been the preferred supplier to some of the top five generic players of the world. Formulations : -Pan-India presence in ethical formulations with a portfolio of close to 70 brands. -Strong presence in gynecology, orthopedics, heamatinics, anti-diabetic, neutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics and general practitioner.

Company Details

Employees
1.19K
Founded
-
Address
Bsel Techpark, B-10 Floor,,
Phone
+91 22 6794 2222
Email
in****@****ury.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Vashi, Navi Mumbai, Maharashtra
Looking for a particular Wanbury Limited employee's phone or email?

Wanbury Limited Questions

News

Wanbury to implement the SAP S/4 HANA private cloud platform - Indian Pharma Post

Wanbury to implement the SAP S/4 HANA private cloud platform Indian Pharma Post

Wanbury's (NSE:WANBURY) Anemic Earnings Might Be Worse Than You Think - simplywall.st

Wanbury's (NSE:WANBURY) Anemic Earnings Might Be Worse Than You Think simplywall.st

Wanbury Unveils 'Wanbury Cred': A Revolutionary Iron Supplement to Combat Anemia - scanx.trade

Wanbury Unveils 'Wanbury Cred': A Revolutionary Iron Supplement to Combat Anemia scanx.trade

Wanbury Secures GMP Certification from Brazil Health Agency; Shares Slump 4% - Equitypandit

Wanbury Secures GMP Certification from Brazil Health Agency; Shares Slump 4% Equitypandit

Wanbury to launch new iron supplement C-RED & API Ketamine - BusinessLine

Wanbury to launch new iron supplement C-RED & API Ketamine BusinessLine

Wanbury reports 88% drop in Q3 FY25 PAT - Indian Pharma Post

Wanbury reports 88% drop in Q3 FY25 PAT Indian Pharma Post

Rajani Associates advises Wanbury Ltd on ₹200 crore NCD issuance - Bar and Bench

Rajani Associates advises Wanbury Ltd on ₹200 crore NCD issuance Bar and Bench

WANBURY Stock Price and Chart — NSE:WANBURY - TradingView

WANBURY Stock Price and Chart — NSE:WANBURY TradingView

Wanbury Appoints Prakash Venkatraman As President Of API Business - BW Healthcare World

Wanbury Appoints Prakash Venkatraman As President Of API Business BW Healthcare World

Wanbury appoints Prakash Venkatraman as president of API business - Pharmabiz.com

Wanbury appoints Prakash Venkatraman as president of API business Pharmabiz.com

Wanbury's Tanuku facility granted GMP certificate by ANVISA - Indian Pharma Post

Wanbury's Tanuku facility granted GMP certificate by ANVISA Indian Pharma Post

Wanbury announces successful completion of US FDA inspection at Patalganga site, Maharashtra - ET HealthWorld

Wanbury announces successful completion of US FDA inspection at Patalganga site, Maharashtra ET HealthWorld

Wanbury under lens for illegal export of diabetes drug - The Economic Times

Wanbury under lens for illegal export of diabetes drug The Economic Times

Lacklustre Performance Is Driving Wanbury Limited's (NSE:WANBURY) Low P/E - simplywall.st

Lacklustre Performance Is Driving Wanbury Limited's (NSE:WANBURY) Low P/E simplywall.st

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility - Indian Pharma Post

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility Indian Pharma Post

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6% - Indian Pharma Post

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6% Indian Pharma Post

Briefs: Wanbury and Bafna Pharmaceuticals - Indian Pharma Post

Briefs: Wanbury and Bafna Pharmaceuticals Indian Pharma Post

Wanbury appoints Pradeep Patni as CEO of India Formulation Business - Indian Pharma Post

Wanbury appoints Pradeep Patni as CEO of India Formulation Business Indian Pharma Post

Wanbury appoints Prakash Venkatraman as President of API business - Express Pharma

Wanbury appoints Prakash Venkatraman as President of API business Express Pharma

Wanbury announces new API product portfolio and launch plans - Express Pharma

Wanbury announces new API product portfolio and launch plans Express Pharma

India’s pharma sector spared from US tariff hikes as Wanbury plans investor visit - BusinessLine

India’s pharma sector spared from US tariff hikes as Wanbury plans investor visit BusinessLine

Wanbury receives CEP certification for Dextromethorphan API from EDQM - Express Pharma

Wanbury receives CEP certification for Dextromethorphan API from EDQM Express Pharma

Wanbury refinances $150 cr debt, cuts interest costs significantly - BusinessLine

Wanbury refinances $150 cr debt, cuts interest costs significantly BusinessLine

Wanbury receives GMP certification from Brazil health regulator for its facility in Raigad, Maharashtra - CNBC TV18

Wanbury receives GMP certification from Brazil health regulator for its facility in Raigad, Maharashtra CNBC TV18

Wanbury gains 5% on conclusion of USFDA inspection at Maharashtra unit with zero observation - CNBC TV18

Wanbury gains 5% on conclusion of USFDA inspection at Maharashtra unit with zero observation CNBC TV18

Wanbury's Patalganga manufacturing facility clears U.S. FDA inspection with zero observations - Express Pharma

Wanbury's Patalganga manufacturing facility clears U.S. FDA inspection with zero observations Express Pharma

After India, European Union to probe Wanbury Pharma for illegal export - The Economic Times

After India, European Union to probe Wanbury Pharma for illegal export The Economic Times

Wanbury's Patalganga facility receives GMP certification from ANVISA - Business Standard

Wanbury's Patalganga facility receives GMP certification from ANVISA Business Standard

Wanbury standalone net profit rises 150.74% in the March 2025 quarter - Business Standard

Wanbury standalone net profit rises 150.74% in the March 2025 quarter Business Standard

Wanbury surges 5% after USFDA issues Zero observations for Patalganga site - Business Standard

Wanbury surges 5% after USFDA issues Zero observations for Patalganga site Business Standard

Wanbury Shares Hit 5% Upper Circuit on API Pipeline and Launches - Equitypandit

Wanbury Shares Hit 5% Upper Circuit on API Pipeline and Launches Equitypandit

Wanbury shares locked in 5% upper circuit on planned API launches, pipeline - Business Standard

Wanbury shares locked in 5% upper circuit on planned API launches, pipeline Business Standard

Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore - The Economic Times

Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore The Economic Times

Wanbury edges higher post conclusion of NCD refinancing at lower rates - Business Standard

Wanbury edges higher post conclusion of NCD refinancing at lower rates Business Standard

Cipla buys 4 key Wanbury brands - The Hindu

Cipla buys 4 key Wanbury brands The Hindu

Cipla buys four women-focused brands from Mumbai-based Wanbury - VCCircle

Cipla buys four women-focused brands from Mumbai-based Wanbury VCCircle

Wanbury consolidated net profit rises 1197.12% in the June 2025 quarter - Business Standard

Wanbury consolidated net profit rises 1197.12% in the June 2025 quarter Business Standard

Cipla acquires four nutraceutical brands of Wanbury - Express Pharma

Cipla acquires four nutraceutical brands of Wanbury Express Pharma

Wanbury to acquire UK generics firm - Business Standard

Wanbury to acquire UK generics firm Business Standard

Wanbury settles Doctors Organic dues at discount - Business Standard

Wanbury settles Doctors Organic dues at discount Business Standard

Wanbury lists with a bang following merger - Business Standard

Wanbury lists with a bang following merger Business Standard

Wanbury implements SAP S/4HANA ERP to drive future ready operations - Business Upturn

Wanbury implements SAP S/4HANA ERP to drive future ready operations Business Upturn

Top Wanbury Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant